Wound Management News

In this video, Michael A. Mont, MD, FAAOS, discussed a recent consensus on wound and dressing management and how it can reduce variability, advance standardization and improve outcomes for patients undergoing total joint arthroplasty.

Healio has compiled March’s most-read news in dermatology.

Chronic graft-versus-host disease was associated with clinically meaningful quality of life impairment and symptom burden, making patient-reported outcomes an important prognostic marker, according to a study.

The FDA’s broad indication for the use of beremagene geperpavec therapy for the treatment of dystrophic epidermolysis bullosa may have large financial implications for payers, according to a study.

Ophthalmic application of beremagene geperpavec was successful in treating recurrent cicatrizing conjunctivitis in one patient with dystrophic epidermolysis bullosa, according to a study.

In addition to cutting edge content, the 22nd annual South Beach Symposium has added a “unique session” that focuses on how the medical and cosmetic dermatologist can work together to holistically treat patients.

People with HIV who were treated with tecovirimat within the first 7 days of mpox symptom onset were 13 times less likely to progress to severe mpox disease compared with those not treated or treated late, a recent study found.

Vyjuvek, the first FDA-approved treatment for dystrophic epidermolysis bullosa, has received a permanent J-code from the Centers for Medicare and Medicaid Services, Krystal Biotech announced in a press release.

The Japanese Ministry of Health, Labour and Welfare has granted Vyjuvek an orphan drug designation for the treatment of dystrophic epidermolysis bullosa, Krystal Biotech announced in a press release.

InflaRx has initiated a phase 3 study of vilobelimab in patients with ulcerative pyoderma gangrenosum, the company announced in a press release.